The incidence of liver cancer in China is very high, because liver cancer is difficult to find in the early stage of the disease. Once the diagnosis is often in the middle and late stages, the optimal treatment time is often missed. The traditional treatment for liver cancer is surgery, radiotherapy and chemotherapy, etc. However, such treatment methods generally have a relatively high recurrence rate, and the survival rate of patients is relatively low. To prevent recurrence and metastasis of liver tumors, cell immunotherapie can be tried at this time.
Due to the limitation of liver tumor size, growth location, and relationship with the position of large blood vessels and biliary tract, some patients with special small liver cancer, huge liver tumor, and middle-advanced liver cancer with multiple metastatic lesions often lose the opportunity for surgery.
However, for these patients, the expert’s approach is to first use argon-helium ultra-cold knife minimally invasive treatment, through physical freezing and thawing to destroy the cell structure of tumor tissue in a short period of time, promote tumor tissue necrosis and close tumor small blood vessels. At the same time, combined with interventional therapy, embolization of tumor large vessels and local high-concentration chemotherapy, the combination of the two therapies can inhibit the growth of liver kankerselle and eliminate tumor lesions in a short period of time.
In general, most of the primary lewerkankers are large undetectable liver cancers, which are accompanied by tumor thrombi in the internal and external portal vein system. The recurrence rate within one year after radiotherapy and chemotherapy is as high as 60%, and the 3-year survival rate is less than 30%. Therefore, the most important thing for liver cancer surgery is to prevent recurrence, but traditional radiotherapy and chemotherapy have large side effects, which can easily lead to liver cirrhosis and even liver function damage.
'N relatief nuwe behandeling metode-biologiese sel immuniteit
(CIK-selle) het 'n beduidende effek op gevorderde lewerkanker. Hierdie terapie kan help om die oorblywende kankerselle in die pasiënt se liggaam skoon te maak, die pasiënt se immuunfunksie om kankerselle te identifiseer en dood te herstel, en sodoende tumormetastase te voorkom en te beheer.
CIK-selle is sitokien-geïnduseerde doderselle, wat mononukleêre selle is wat uit perifere bloed, beenmurg of naelstringbloed geïsoleer is. Na 'n sekere tydperk in die laboratorium, word hulle geïnduseer, geprolifereer en dan weer in die pasiënt gevoeg om die bloed direk dood te maak. Tumorselle in die limf reguleer en verbeter ook die pasiënt se immuunfunksie.
Volgens kliniese statistieke ondergaan 9 pasiënte met stadium 4 lewerkanker meer as 3 siklusse van selimmunoterapie na chirurgie, wat herhaling van lewerkanker na chirurgie beter kan voorkom. Die gemiddelde oorlewingstyd na behandeling is 20 maande, en die herhalingsyfer binne 1 jaar is slegs 22.2%, en die ongemaksimptome van die meeste pasiënte is verbeter
Die bogenoemde eenvoudige begrip van die voorkoming van lewertumor herhaling en metastase, kan jy probeer sel immunoterapie, sel immunoterapie is 'n relatief nuwe metode van die behandeling van kanker, soos biologiese sel immunoterapie, kan pasiënte help verwyder oorblywende kankerselle in die liggaam, bykomend tot immuniteit Terapie het die effek om kankerselle te identifiseer en dood te maak en sodoende die verspreiding en metastase van gewasse verder te voorkom.
